PMID: 26319381Sep 1, 2015Paper

Factors predisposing to the reprogramming of implantable cardioverter-defibrillators and the causes of changes in pharmacotherapy in patients with dilated cardiomyopathy for primary prevention of sudden cardiac death

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
Joanna PudłoJacek Nowak

Abstract

Ambulatory care of patients with implantable cardioverter-defibrillator (ICD) involves regular follow-up visit, where a decision on reprogramming of the device and modification of pharmacotherapy is made. The aim of the study was the assessment of frequency and reasons of reprogramming and pharmacotherapy changes in patients with dilated cardiomyopathy with an ICD implanted due to primary prevention of sudden cardiac death (SCD). The study included 143 consecutive patients with an ICD implanted in 2010-2011. The inclusion criteria were: left ventricle ejection fraction (LVEF)≤35%, New York Heart Association (NYHA) Class≥II, implantation due to primary prevention of SCD. All ambulatory visits in outpatient department were investigated retrospectively. The following variables were analyzed: age, gender, presence of coronary artery disease (CAD) and atrial fibrillation (AF), LVEF, NYHA class, presence of interventions, reprogramming and pharmacotherapy changes. The most common changes in ICD parameters were modification of detection and therapy of ventricular arrhythmias. Modification of pharmacotherapy were most often referred to B-blocker and cardiac glycosides. Patients with AF had more often parameters of bradycardia pacing ch...Continue Reading

Related Concepts

Related Feeds

Cardiac Glycosides

Cardiac glycosides are a diverse family of naturally derived compounds that bind to and inhibit na+/k+-atpase. Discover the latest research on cardiac glycosides heres.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
Ganesh S KamathMark V Sherrid
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
Karin KraaierPascal F H M van Dessel
© 2021 Meta ULC. All rights reserved